PDE6B and tuberculosis: Future work that combines well-defined PLWH (including people on antiretroviral therapy) and individuals without HIV from areas of high and low TB endemicity will be needed to advance the evaluation of Mtb-specific IgGs, especially antibodies to RD-1 proteins (to avoid cross reactivity with BCG vaccination) as potential biomarkers for LTBI detection.